… The degree of risk associated with antiphospholipid antibody depends on the characteristics
of the antiphospholipid antibody profile and on the presence of additional thrombotic risk …

… In this study we described the real-world experience of 39 CAPS patients treated with
eculizumab, a humanized monoclonal antibody that binds to the C5 complement protein. Despite …

… Antiphospholipid syndrome (APS) is a rare and complex autoimmune disorder … thrombosis
and pregnancy complications in the presence of antiphospholipid antibodies (aPL), including …

… Small vessel thrombosis is best described in the context of catastrophic antiphospholipid
syndrome (CAPS), where it is a defining criteria [68,69], but is outwith the scope of this review. …

… of patients with catastrophic antiphospholipid syndrome who present with features of a
complement mediated thrombotic microangiopathy, real world experience has not found such …

… It refers to patients who meet laboratory criteria for APS and have experienced prior … The
term “catastrophic” antiphospholipid syndrome (CAPS) was introduced in 1992 to describe a life-…

… list all features that, in their experience, occur as part of the aPL/… encouraged to consider
their real-life experience with aPL-… /II methodology of the new antiphospholipid syndrome (APS) …

… proportion of patients continue to experience thrombosis and pregnancy morbidity despite
this … study has demonstrated that conventional anticoagulant treatment has improved the life …

… Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by
obstetric morbidity, arterial and/or venous thrombosis in the presence of antiphospholipid …

… ) are increasingly used in antiphospholipid syndrome (APS). … K antagonists (VKAs) in real-life
consecutive APS patients. … %) experienced stroke/TIA and 16 (19%) subjects experienced …